PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ventech Financial

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Covagen Adds Ventech to Investor Syndicate and Further Strengthens its Scientific Advisory Board - Covagen announced closing of a financing round with Ventech joining as a new investor. Covagen also announced today that it expanded its Scientific Advisory Board - VentechVC.fr
Covagen Adds Ventech to Investor Syndicate and Further Strengthens its Scientific Advisory Board

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2009/12/01 - Covagen announced closing of a financing round with Ventech joining as a new investor. Covagen also announced today that it expanded its Scientific Advisory Board - VentechVC.fr.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Covagen, an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomers), announced today the closing of a financing round with Ventech joining as a new investor.
“We are very pleased that we could attract an additional internationally renowned venture firm to invest into Covagen. The additional funding provided by Ventech validates the interest in our technology and discovery projects and will allow us to accelerate to progress into development”, said Dr. Julian Bertschinger, Chief Executive Officer of Covagen. Dr. Karl Nägler of Ventech, who will join Covagen’s Board, added: “There continues to be significant interest in small binding proteins and we are convinced that Covagen is best positioned to fulfill the demand for differentiated pharmacology based on the versatility of its Fynomer platform.”

Covagen also announced today that it has further strengthened its Scientific Advisory Board, which will be expanded by two industry experts with strong background in inflammation and oncology.

Prof. Christoph Lengauer is VP & Global Head of Oncology, Discovery Research at sanofi-aventis. Before joining sanofi-aventis, he was Executive Director & Senior Unit Head, Oncology Discovery at the Novartis Institutes for Biomedical Research (NIBR). In 2007, he received the Top Innovator – Novartis Oncology President’s Award. Prior to Novartis, Dr. Lengauer served as Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore (USA).

Dr. Lengauer studied Human Genetics in Salzburg, Austria, and obtained his Ph.D. in 1992 from the University of Heidelberg, Germany. He did his postdoctoral research at the Research Institute of Molecular Pathology (IMP) in Vienna and then in the laboratory of Profs. Bert Vogelstein & Ken Kinzler at the Johns Hopkins University School of Medicine in Baltimore. Dr. Lengauer is lead author of several scientific articles that have been published in highly esteemed journals such as Nature and Science.
“Covagen has recently made substantial progress towards validating the full potential of its technology”, said Dr. Lengauer. “I feel honored for being chosen to support the company at this interesting stage of its development.”

Dr. Christoph Heusser served as Head of Biologics in Anti-inflammatory Diseases & Transplantation Research at NIBR and member of the Biologic Advisory Board at Novartis until his retirement in November 2009. Previously, he was Head of the Immunology Section at Ciba and later at Novartis with a focus on therapeutic antibodies. Dr. Heusser studied biochemistry at the Swiss Federal Institute of Technology, Zürich. After obtaining his PhD in 1974 at the University of Lausanne and Swiss Federal Institute of Technology, Dr. Heusser worked at the Department of Medicine, Allergy and Clinical Immunology Section, at the Denver Medical Center as a postdoctoral fellow, and in 1976, he became a member of the Basel Institute of Immunology. In 1979, Dr. Heusser joined Ciba-Geigy, which later became Novartis, where he introduced the concept of using anti-IgE antibodies for the treatment of rhinitis and allergic asthma. This work formed the basis for the clinical development of Xolair (Novartis/ Genentech) which was approved by the FDA in 2003.
“I think that the Fynomer technology is very exciting”, said Dr. Heusser. “I am looking forward to helping Covagen’s team to bring their promising Fynomer drug candidates through preclinical to clinical development.”

“We are very proud that we were able to attract Dr. Heusser and Dr. Lengauer to our Scientific Advisory Board”, added Dr. Julian Bertschinger. “They will be very valuable for the further development of Covagen.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Ventech Financial

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Financial/Legal/Venture articles,
CATCH Visitors via Your Competitors Announcements!


Covagen Adds Ventech to Investor Syndicate and Further Strengthens its Scientific Advisory Board

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Karl Naegler - VentechVC.com 
+33(0)1 58 19 84 76 karl.naegler[.]ventechvc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ventech Financial securities in any jurisdiction including any other companies listed or named in this release.

Financial/Legal/Venture via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Ventech Financial / Company Profile


Read Financial/Legal/Venture Most Recent Related Newswires:

Infinera to Participate in Upcoming Investor Conference
Propel Financial Services Partners with Clear Payment Solutions
Digital Payments Power Growth in Booming Asia-Pacific Financial Technology Landscape Notes Frost & Sullivan
Digital Readiness Key to Growth Opportunities in the Financial Services Market
Prairie Capital Advisors Announces The Sale of Cornerstone Treatment Facilities Network to An ESOP
Koch Agrees to Invest Over $2 Billion in Infor
FTI Consulting Recognized as a Top Service Provider in the Legal Industry
GE Completes Spin Off and Demerger of Bank BPH Core Bank to Alior Bank
ALM Expands Senior Leadership Team, Organization Focused on Customers and Transformation
Lazard Acquires Remaining 50% Stake in MBA Lazard - Fully Integrating its Latin American Operations
Western Union Business Solutions Announce Mark Davis As Head of Australia and New Zealand
Tabarak Investment Capital and Elite Capital & Co. Limited in Discussion to Finance Projects
Consulting Magazine Unveils the Profession’s Fastest Growing Firms At Inaugural Gala
Hills Invest Signs An Agreement with The Afore Profuturo in Mexico
TRA Searches for TPA Acquisition Opportunities

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)